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Introduction {#sec1}
============

Mutations in the Crumbs homolog-1 (*CRB1*) gene are linked to an array of retinal dystrophies that exhibit high phenotypic variability and affect approximately 80,000 patients worldwide with an estimated prevalence in the US of 1/86,500 ([@bib3], [@bib43], [@bib45]). A meta-analysis has found that mutations in the *CRB1* gene account for 2.7% and 10.1% of autosomal recessive retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA) cases, respectively ([@bib9]). LCA is an early-onset disease, with newborns being blind around birth. However, we are yet to understand the localization of the CRB complex in early human fetal retinal development. No treatment is currently available for *CRB1*-associated retinal dystrophy in patients, but proof-of-concept gene supplementation studies have shown both morphological and functional rescue in *CRB1* RP mouse models ([@bib32]). A retrospective cohort study of patients with *CRB1*-associated RP has shown that gene therapeutic intervention is most likely required within the first three decades of life, but clinical endpoint criteria for a clinical trial need to be established from natural history studies ([@bib45]). Preclinical considerations to be evaluated include the choice of adeno-associated virus (AAV) serotype for delivery of the clinical vector, in terms of potency, tropism, safety, and biodistribution.

Some retinal gene therapies use a serotype of AAV as a delivery vector in clinical trials ([@bib23], [@bib24], [@bib40]) because it restricts vector tropism to specific retinal subpopulations, improves the efficiency of gene delivery, has low immunogenicity and long transgene expression. Cross-species differences in vector tissue tropism between mice and non-human primates have been previously highlighted and must be sufficiently addressed before moving toward clinical trials ([@bib5], [@bib38]). We previously showed proof-of-concept for *CRB1* gene therapy in *Crb1*-retinitis pigmentosa-like mice by subretinal application of an AAV9-CMV-*CRB2* gene therapy vector, thereby demonstrating the need for transgene expression in both photoreceptors and Müller glial cells (MGCs) ([@bib32]). On subretinal application, AAV9 and the AAV6 variant serotype ShH10Y445F are able to efficiently infect mouse photoreceptors, MGCs, and retinal pigment epithelium, whereas AAV5 does not efficiently infect and express in mouse MGCs ([@bib1], [@bib30]). AAV tropism differs between species, therefore the AAV serotype for clinical *CRB1* gene therapy in both photoreceptors and MGCs needs to be validated. AAV5 and AAV9 infect non-human primate rod and cone photoreceptors ([@bib7], [@bib47]). Human induced pluripotent stem cell (hiPSC)-derived retinal organoids, although *in vitro*, are a promising alternative or additional/pre-screening tool to animal models for evaluating transgene expression and biological activity ([@bib35]). As previously demonstrated by others and ourselves hiPSC-derived retinal organoids and photoreceptors are amenable for the testing of AAV serotype/promoter combinations ([@bib17], [@bib35], [@bib48]). However, for this purpose the hiPSC-derived retinal organoids should suitably recapitulate the human retina and the onset of expression of its proteins.

The core Crumbs complex in mammals is comprised of CRB1-3, PALS1 (also called MPP5), MUPP1, and PATJ. The prototypic CRB protein has a large extracellular domain with epidermal growth factor-like domains and laminin-A globular domains adjacent to a single transmembrane domain. A short C terminus of 37 amino acids contains an FERM protein-binding domain juxtaposing the single transmembrane domain. At the C-terminal end, there is a PDZ protein-binding motif of four amino acids (ERLI) that allows interaction with adaptor proteins such as PALS1 and PAR6 ([@bib6], [@bib10], [@bib21], [@bib41]). In non-human primates, CRB1 and CRB2 proteins localize to the subapical region adjacent to adherens junctions in MGCs and photoreceptors ([@bib37]). Similarly, in 2-day-old human adult cadaveric retina, both CRB1 and CRB2 are located at the subapical region in MGCs. However, in photoreceptors, the CRB1 protein is detectable at the subapical region near the outer limiting membrane (OLM), but CRB2 is not. In addition, both CRB1 and CRB2 are detected at vesicles in the photoreceptor inner segments at a distance from the OLM ([@bib31], [@bib32]). Thus far, the localization of the CRB complex in early human fetal retinal development is unknown.

In this study, we show the recapitulation of the CRB complex between the human fetal retina and cultured hiPSC-derived retinal organoids. These studies highlight that CRB2, but not CRB1, is present at the subapical region in human fetal retina during the first trimester of pregnancy. CRB1 is expressed only at later time points from the second trimester onwards, concurring with the birth of differentiated cell types such as photoreceptors and MGCs. These data suggest role(s) for CRB2 but not CRB1 in the first trimester in the earliest human retinal radial glial progenitor cells. The data also suggest that *CRB1* patient iPSC-derived retinal organoids develop a retinal phenotype as found in *Crb1*^*KO*^ and *Crb1*^*KO/C249W*^ mice ([@bib25], [@bib26], [@bib27]).

In addition, we show higher efficacy of AAV5 and ShH10Y445F over AAV9 serotypes for infection of photoreceptors in cultured human donor retinal explants. We also show the preference of AAV5 and ShH10Y445F over AAV9 to infect MGCs in hiPSC-derived retinal organoids. Overall, our results suggest that the AAV5 serotype, combined with CMV promoter-mediated expression, is suitable for gene therapy for *CRB* genes into human MGCs and rod and cone photoreceptors.

Results {#sec2}
=======

Retinal Architecture in the Human Fetal Retina and iPSC Retinal Organoids {#sec2.1}
-------------------------------------------------------------------------

The human fetal retina, as it transitions from the first to the second trimester of pregnancy, gives rise to all adult retinal cell types as the retina moves from a mitotic to post-mitotic state ([@bib34]). We examined first (weeks 11--13) and second trimester (weeks 16--18) fetal retina and compared these with early (differentiation day 30 \[DD30\]) and late (DD120--DD240) healthy hiPSC retinal organoids. The retinal architecture in the human fetal retina recapitulated the retinal architecture as found in hiPSC retinal organoids ([Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}).

The CRB Complex in the Human Fetal Retina and iPSC Retinal Organoids {#sec2.2}
--------------------------------------------------------------------

We undertook immunohistochemistry studies to delineate the onset of expression of CRB1 and CRB2 in first and second trimester human fetal retina and in early and late stage differentiated retinal organoids.

In week 9 human fetal retina we did not detect the typical puncta-like CRB1^+^ immunostaining at the subapical region adjacent to the adherence junction marker β-catenin ([Figures S3](#mmc1){ref-type="supplementary-material"}A--S3C). However, at week 11 we observed a gradient of CRB1 immunostaining located at the OLM ([Figure 1](#fig1){ref-type="fig"}A). In weeks 9 and 11, the human fetal retina stained positive for CRB2 at the subapical region adjacent to the adherence junctions as marked by anti-p120-catenin ([Figures 1](#fig1){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}D--S3F). Furthermore, in the first trimester fetal retina at week 9 ([Figures S3](#mmc1){ref-type="supplementary-material"}G--S3I), we found PATJ at the OLM and additionally in a subset of anti-Ki67^+^ cells; this was also seen in the developing mouse retina ([@bib2]). In week 19, the human fetal retina expressed CRB1 ([Figure 1](#fig1){ref-type="fig"}E) and CRB2 ([Figure 1](#fig1){ref-type="fig"}F) with their prototypic puncta immunostaining pattern. Immunostaining for CRB complex members PALS1, MUPP1, PAR3, and the adherens junction markers β-catenin, p120-catenin, and N-cadherin were detected in both first and second trimester human fetal retina ([Figure 1](#fig1){ref-type="fig"}).Figure 1Localization of the CRB Complex at the Outer Limiting Membrane in Human Fetal and iPSC-Derived Human RetinaImmunohistochemistry pictures of first (A--D) and second (E--H) trimester human fetal retina and early (I and J) and late (K--O) LUMC0004iCTRL10 hiPSC-derived retinal organoids. Sections were stained for subapical region markers: CRB1 (A, E, I, and K), CRB2 (B, F, J, and L) PALS1 (C, G, and M), PAR3 (D, H, and O), MUPP1 (D, H, and N) and for adherens junction markers: β-catenin (A and K), p120-catenin (B and L), N-cadherin (C, G, and M). OLM, outer limiting membrane. Scale bars, 20 μm (A--O). See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

Similarly, In DD28 and DD80 retinal organoids we did not detect typical CRB1^+^ puncta-like immunostaining ([Figures 1](#fig1){ref-type="fig"}I and [S3](#mmc1){ref-type="supplementary-material"}J). Its family member CRB2 was present at DD28 and DD80 ([Figures 1](#fig1){ref-type="fig"}J and [S3](#mmc1){ref-type="supplementary-material"}K). PALS1 and MUPP1 were present at the subapical region in DD28 hiPSC-derived retinal organoids ([Figures S3](#mmc1){ref-type="supplementary-material"}L and S3M). Moreover, in retinal organoids at DD30 ([Figures S3](#mmc1){ref-type="supplementary-material"}N--S3P) we found PATJ at the OLM, and additionally in a subset of anti-Ki67^+^ cells. However, a typical and clear puncta-like staining pattern for CRB1 was detected at DD160 subapical of adherens junctions marker β-catenin ([Figure 1](#fig1){ref-type="fig"}K). CRB complex members CRB2, PALS1, MUPP1, and PAR3, and adherens junction markers p120-catenin and N-cadherin, were also detected in DD160 retinal organoids ([Figures 1](#fig1){ref-type="fig"}L--1O). CRB1 and CRB2 localization in retinal organoids was also confirmed in two other hiPSC lines: LUMC0080iCTRL12 ([Figures S3](#mmc1){ref-type="supplementary-material"}Q--S3S) and LUMC0044iCTRL44 ([Figures 5](#fig5){ref-type="fig"}E--5H and [6](#fig6){ref-type="fig"}E--6H).

Ultra-Localization of CRB1 and CRB2 in the Human Fetal Retina and in iPSC Retinal Organoids {#sec2.3}
-------------------------------------------------------------------------------------------

We performed immunoelectron microscopy (immuno-EM) studies to analyze, at ultra-high resolution, the localization of CRB1 and CRB2 in photoreceptor cells (PRCs) and MGCs in first and second trimester human fetal retina and in retinal organoids. Immuno-EM for CRB1 in the first trimester fetal retina showed occasional and limited staining at putative inner segments ([Figure 2](#fig2){ref-type="fig"}A) and apical villi ([Figure 2](#fig2){ref-type="fig"}B) of radial glial progenitor cells. However, in the second trimester CRB1 labeling could be clearly detected at the subapical region adjacent to adherens junctions between putative photoreceptor inner segments ([Figure 2](#fig2){ref-type="fig"}C) and in the apical villi of radial glial progenitor cells/MGCs ([Figure 2](#fig2){ref-type="fig"}D). Immuno-EM for CRB2 showed pronounced labeling in first ([Figures 3](#fig3){ref-type="fig"}E and 3F) and second trimester ([Figures 2](#fig2){ref-type="fig"}G and 2H) fetal retina. CRB2 labeling localized at the plasma membrane and at the subapical region adjacent to adherens junctions between putative photoreceptor inner segments ([Figures 2](#fig2){ref-type="fig"}E and 2G) and in the apical villi of radial glial progenitor cells/MGCs ([Figures 2](#fig2){ref-type="fig"}F and 2H).Figure 2CRB1 and CRB2 are Located at the Outer Limiting Membrane in Müller Glial Cells and Photoreceptors of First and Second Trimester Human Fetal RetinaImmuno-EM staining showing the localization of CRB1 (A--D) and CRB2 (E--H) in first (A, B, E, and F) and second (C, D, G, and H) trimester human fetal retina. CRB1 was sporadically detected in the first trimester but being found subapically of adherens junctions adjacent to photoreceptor inner segments (A) (arrow) and in Müller glial cell apical villi (B) (arrowheads). In the second trimester, CRB1 was found consistently throughout the outer limiting membrane of human fetal retina subapically of adherens junctions of photoreceptors and Müller glial cells (C and D). CRB2 was localized in both first and second trimester retina subapically of adherens junctions being located in photoreceptor inner segments and apical villi of Müller glial cells. At least two independent samples were analyzed per time point. CC, connecting cilium; AJ, adherens junction; μ, microvilli; IS, inner segment. Scale bar (A--H), 1 μm; insert (D), 500 nm.Figure 3CRB1 and CRB2 are Located at the Outer Limiting Membrane in Müller Glial Cells and Photoreceptors of Human iPSC-Derived Retinal OrganoidsImmuno-EM staining showing the localization of CRB1 (A--D) and CRB2 (E--H) in DD120 (A, B, E, and F) and DD170 (C, D, G, and H) LUMC0004iCTRL10 human iPSC-derived retinal organoids. CRB1 was lowly and sporadically detected at DD120 but being found subapically of adherens junctions adjacent to photoreceptor inner segments (A) (arrow) and in Müller glial cell apical villi (B) (arrowheads). At DD170, CRB1 was found consistently throughout the outer limiting membrane of human iPSC-derived retinal organoids subapically of adherens junctions of photoreceptors and Müller glial cells (C and D). CRB2 was localized at both DD120 and DD170 subapically of adherens junctions being located in photoreceptor inner segments and apical villi of Müller glial cells. At least two independent samples were analyzed per time point. CC, connecting cilium; AJ, adherens junction; μ, microvilli; IS, inner segment. Scale bar (A--H), 1 μm; insert (B and C), 500 nm.

Similarly to first trimester human fetal retina, immuno-EM performed on retinal organoids showed sporadic and limited CRB1 labeling at the subapical region adjacent to adherens junctions between putative photoreceptor inner segments ([Figure 3](#fig3){ref-type="fig"}A) and in the apical villi of radial glial progenitor cells/MGCs ([Figure 3](#fig3){ref-type="fig"}B) in early retinal organoids. However, in late retinal organoids CRB1 labeling localized at the plasma membrane and at the subapical region adjacent to adherens junctions between putative photoreceptor inner segments ([Figure 3](#fig3){ref-type="fig"}C) and in the apical villi of radial glial progenitor cells/MGCs ([Figure 3](#fig3){ref-type="fig"}D). Immuno-EM for CRB2 showed pronounced labeling in early ([Figures 3](#fig3){ref-type="fig"}E and 3F) and late ([Figures 3](#fig3){ref-type="fig"}G and 3H) retinal organoids. CRB2 labeling localized at the plasma membrane and at the subapical region adjacent to adherens junctions between putative photoreceptor inner segments ([Figures 3](#fig3){ref-type="fig"}E and 3G) and in the apical villi of radial glial progenitor cells/MGCs ([Figures 3](#fig3){ref-type="fig"}F and 3H).

Taken together, these data suggest that CRB1 is not required for the localization of CRB2, PALS1, MUPP1, or PATJ in the first trimester of human retinal development. The onset of CRB protein expression in human fetal retina is recapitulated in retinal organoids.

Disruptions at the OLM in Retinal Organoids from *CRB1* RP Patients {#sec2.4}
-------------------------------------------------------------------

We generated three hiPSC lines (LUMC0116iCRB, LUMC0117iCRB, and LUMC0128iCRB) from *CRB1* RP patients. As with healthy iPSCs ([Figure S4](#mmc1){ref-type="supplementary-material"}A), patient iPSCs were validated via immunostaining with pluripotent and germ layer markers ([Figure S4](#mmc1){ref-type="supplementary-material"}B). LUMC0116iCRB has c.3122T \> C p.(Met1041Thr) homozygote missense mutations. LUMC0117iCRB has 2,983G \> T p.(Glu995^∗^) and c.1892A \> G, p.(Tyr631Cys) mutations. LUMC0128iCRB has c.2843G \> A p.(Cys948Tyr) and c.3122T \> C p.(Met1041Thr) missense mutations. The *CRB1* gene mutations were re-confirmed in the established iPSCs ([Figure S4](#mmc1){ref-type="supplementary-material"}C).

*CRB1* patient iPSCs were able to differentiate to DD180 retinal organoids and were compared with healthy retinal organoids ([Figure 4](#fig4){ref-type="fig"}). The patient retinal organoids had pH3^+^ mitotic cells apically at the OLM, with Ki67^+^ cycling cells less tightly restricted to the middle of the neurobasal layer (NBL) ([Figures 4](#fig4){ref-type="fig"}I, 4M, and 4Q). The *CRB1* patient iPSCs retinal organoids developed all three retinal layers: a ganglion cell layer marked by Tuj1^+^ dendrites ([Figures 4](#fig4){ref-type="fig"}J, 4N, and 4R), an NBL marked by SOX9^+^ retinal progenitor cells/MGCs ([Figures 4](#fig4){ref-type="fig"}K, 4O, and 4S), and an outer nuclear layer (ONL) marked by recoverin^+^ PRCs ([Figures 4](#fig4){ref-type="fig"}L, 4P, and 4T). However, frequent ectopic cells were found above the OLM ([Figures 4](#fig4){ref-type="fig"}I--4T). We observed many areas of funnel-shaped outward protruding recoverin^+^ PRCs ([Figures 4](#fig4){ref-type="fig"}L, 4P, and 4T) and, sporadically, SOX9^+^ cells above the OLM ([Figure 4](#fig4){ref-type="fig"}O).Figure 4*CRB1* Patient Retinal Organoids Develop Proper LaminationImmunohistochemistry pictures of healthy (LUMC0004iCTRL10 and LUMC0044iCTRL44) versus *CRB1* patient (LUMC0116iCRB09, LUMC0117iCRB01, and LUMC0128iCRB01) retinal organoids at DD180. Sections were stained for pH3^+^ mitotic cells and Ki67^+^ cycling cells (A, E, I, M, and Q); Tuj1^+^ dendrites marking the GCL (B, F, J, N, and R); SOX9^+^ NBL cells (C, G, K, O, and S); and recoverin^+^ PRCs marking the ONL (D, H, L, P, and T). Experiments were validated in two differentiations for retinal organoids. NBL, neurobasal layer; GCL, ganglion cell layer. Scale bars (A--T), 20 μm. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

All retinal organoids from the three different *CRB1* patient lines developed small but frequent disruptions of CRB complex members at the OLM that were not detected in control lines ([Figure 5](#fig5){ref-type="fig"}). The adherens junction proteins N-cadherin, p120-catenin, β-catenin, and the subapical region proteins CRB2, PALS1, PAR3, and MUPP1 were localized as in healthy retinal organoids at DD180 ([Figure 5](#fig5){ref-type="fig"}). Interestingly, CRB1 variant protein localized similar to the wild-type CRB1 protein at the subapical region above the adherens junctions, but showed a curved and broadened expression pattern ([Figures 5](#fig5){ref-type="fig"}I, 5M, 5Q, and 5U) compared with the healthy control lines ([Figures 5](#fig5){ref-type="fig"}A and 5E). CRB1 variant protein was also mislocalized in the apical area of the NBL and in the ONL ([Figures 5](#fig5){ref-type="fig"}I, 5M, and 5Q). The mislocalized PRCs above the OLM resided at areas of OLM disruptions ([Figures 5](#fig5){ref-type="fig"}V, 5W, and 5X). In conclusion, the data from *CRB1* patient hiPSC retinal organoids suggest a retinal degeneration phenotype similar to that previously found in mice lacking CRB1 or expressing variant CRB1^C249W^ ([@bib25], [@bib26], [@bib27]).Figure 5*CRB1* Patient Organoids Develop Retinal DegenerationImmunohistochemistry pictures of healthy: LUMC0004iCTRL10 (A--D and A′--D′) and LUMC0044iCTRL44 (E--H, E′--H′) retinal organoids at DD180; and *CRB1* patient: LUMC0116iCRB09 (I--L, I′--L′, U, and V), LUMC0117iCRB01 (M--P, M′--P′, and W), LUMC0128iCRB01 (Q--T, Q′--T, and X) retinal organoids at DD180. Sections were stained for subapical region markers: CRB1 (A, E, I, M, Q, and U), CRB2 (B, F, J, N, and R), PALS1 (C, G, K, O, S, V, W, and X), PAR3 (D, H, L, P, and T), MUPP1 (D, H, L, P, and T); and for adherens junction markers: β-catenin (A, E, I, M, Q, and U), p120-catenin (B, F, J, N, and R), and N-cadherin (C, G, K, O, S, and V). Disruptions of the OLM are seen in patient retinal organoids (I--T and I′--T′) with recoverin^+^ photoreceptors found displaced (V--X). (A--X) Counterstained with DAPI. Experiments were validated in two differentiations for retinal organoids. OLM, outer limiting membrane; NBL, neurobasal layer. Scale bars (A--X), 20 μm. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

Transduction of Human iPSC Retinal Organoids with AAV5, AAV9, and ShH10Y445F {#sec2.5}
----------------------------------------------------------------------------

Human iPSC-derived retinal organoids are a promising tool for evaluating transgene expression and biological activity ([@bib35]). We have shown the need in *Crb1-*retinitis pigmentosa-like mice to direct *CRB* gene therapy to both photoreceptors and MGCs ([@bib32]). Choosing the optimal promoter and AAV serotype for the therapeutic vector is therefore crucial to achieving expression in photoreceptors and MGCs. Here, we transduced the hiPSC-derived retinal organoids with AAV9-CMV-*GFP*, AAV5-CMV-*GFP*, ShH10Y445F-CMV-*GFP*, and ShH10Y445F-RLBP1-*GFP* at 10^10^ genome copies (gc). The CMV promoter drives expression of GFP in multiple cell types, whereas the hRLBP1 promoter drives expression in MGCs and retinal pigment epithelial cells ([@bib30]). When analyzed at the same laser intensity settings ([Figures S5](#mmc1){ref-type="supplementary-material"}A--S5D) AAV5-CMV-*GFP*, ShH10Y445F-CMV-*GFP*, and ShH10Y445F-hRLBP1-*GFP* significantly outperformed AAV9-CMV-*GFP* at transducing DD220 hiPSC-derived retinal organoids collected 14 days after infection ([Figures 6](#fig6){ref-type="fig"}E and 6F). We quantified both the number of GFP^+^ cells per total cells ([Figure 6](#fig6){ref-type="fig"}E) and the mean gray value ([Figure 6](#fig6){ref-type="fig"}F) for each vector. The GFP^+^ nuclei were mainly located in the inner retina and exhibited radial projections. The GFP^+^ nuclei co-localized with anti-LHX2 ([Figures 6](#fig6){ref-type="fig"}A--6D, inserts) and anti-SOX2 ([Figures S5](#mmc1){ref-type="supplementary-material"}E--S5H and S5E′--S5H′), both transcription factors required for MGC development. Further proof of Müller glial-specific transduction is also seen with the use of ShH10Y445F-RLBP1-*GFP* ([Figure 6](#fig6){ref-type="fig"}D), which drives GFP in MGCs in rat and mouse retinas ([@bib18], [@bib30]). We additionally stained with anti-recoverin and found occasional co-localization between the photoreceptor marker and GFP^+^ nuclei ([Figures S5](#mmc1){ref-type="supplementary-material"}I--S5L and S5I′--S5L′). In conclusion, these results indicate that AAV5 and ShH10Y445F serotypes are more potent transducers of MGCs than AAV9 in hiPSC-derived retinal organoids.Figure 6AAV5 and ShH10Y445F Efficiently Infect Müller Glial Cells in Human iPSC Retinal Organoids and Photoreceptors and Müller glial Cells in the Human Adult Retina(A--F) Infection of 7.5-month-old LUMC0004iCTRL10 hiPSC retinal organoids at 10^10^ gc with AAV9-CMV-*GFP* (A), AAV5-CMV-*GFP* (B), ShH10Y445F-CMV-*GFP* (C), and ShH10Y445F-RLBP1-*GFP* (D), and co-staining with the Müller glial cell marker LHX2, the majority of LHX2^+^ cells were also GFP^+^ (asterisk). Efficacy of transducing retinal cell types was quantified by measuring the number of GFP^+^ cells in the total cell population (E) and fluorescence (MGV) (F). AAV5 and ShH10Y445F showed the higher efficacy of transducing retinal cell types at 10^10^ gc than AAV9, which showed lower efficacy. A total of 10^10^ gc applied per two organoids, two independent differentiations used, three to four organoids analyzed per vector.(G--Q) Infection of human retinal explants with AAV9-CMV-*GFP* at 3 × 10^11^ gc (G and K) and 3 × 10^10^ gc (H and L), AAV5-CMV-*GFP* at 3 × 10^10^ gc (I and M), and ShH10Y445F-CMV-*GFP* at 3 × 10^10^ gc (J and N). Co-staining showed the presence of GFP^+^/Sox9^+^ Müller glial cells with AAV9 (G and H), AAV5 (I), and ShH10Y445F (J). Co-staining showed the presence of GFP^+^/recoverin^+^ photoreceptors AAV9 (K and L), AAV5 (M), and ShH10Y445F (N). Efficacy of transducing retinal cell types at 3 × 10^10^ gc was quantified by measuring the number of GFP^+^ cells in the total cell population (O). When compared for three donors at 3 × 10^10^ gc, AAV5 showed higher efficacy of transducing retinal cell types than AAV9. The potency of AAV serotypes was compared by analyzing transduction of cell types in each of the ONL, INL, and GCL (P). AAV5 and ShH10Y445F showed higher potency in transduction of photoreceptors in the ONL than AAV9. All serotypes transduced cells in all layers at 3 × 10^10^ gc (Q). Each dot represents the average of an individual donor (O and P), 10 images were analyzed per donor (O--Q). ONL, outer nuclear layer; INL, inner nuclear layer; GCL, ganglion cell layer; gc, genome copies; MGV, mean gray value.Scale bar (A--D, G--N), 20 μm; (A--D, G--N) inserts, 10 μm. Data are presented as means ± SEM. ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001.See also [Figures S5--S7](#mmc1){ref-type="supplementary-material"}.

Transduction of Adult Postmortem Human Retinal Explants with Serotypes AAV5, AAV9, and ShH10Y445F {#sec2.6}
-------------------------------------------------------------------------------------------------

To verify the results of our transduction studies on hiPSC-derived retinal organoids we also tested AAV9-, AAV5-, and ShH10Y445F-CMV-*GFP* on human adult retinal explants. Initially, a titration study for AAV9 ([Figures S6](#mmc1){ref-type="supplementary-material"}A--S6C), AAV5 ([Figures S6](#mmc1){ref-type="supplementary-material"}D--S6F), and ShH10Y445F ([Figures S6](#mmc1){ref-type="supplementary-material"}G--S6I) was undertaken to determine what gc level is required to infect photoreceptors and MGCs efficiently. Analysis for total infection ([Figures S6](#mmc1){ref-type="supplementary-material"}P and S6Q), infection per retinal layer ([Figures S6](#mmc1){ref-type="supplementary-material"}R and S6S), and tropism ([Figure S6](#mmc1){ref-type="supplementary-material"}T) in donor 1 indicated 3 × 10^10^ gc as a suitable level. Similar transduction patterns were found in donor 1 ([Figures 6](#fig6){ref-type="fig"}H--6K, 6L--6N, [S6](#mmc1){ref-type="supplementary-material"}B, S6D, and S6G), donor 2 ([Figures S6](#mmc1){ref-type="supplementary-material"}J--S6L), and donor 3 ([Figures S6](#mmc1){ref-type="supplementary-material"}M--S6O) at 3 × 10^10^ gc. With individual analysis for total infection ([Figures S6](#mmc1){ref-type="supplementary-material"}U, S6V, S6Y, and S6Z), infection per retinal layer ([Figures S6](#mmc1){ref-type="supplementary-material"}W and S6AA), and tropism ([Figures S6](#mmc1){ref-type="supplementary-material"}X and S6BB) also done for donors 2 and 3 at 3 × 10^10^ gc. Donors 1--3 had similar retinal layer thickness ([Figure S6](#mmc1){ref-type="supplementary-material"}CC) and cells per retinal layer ([Figure S6](#mmc1){ref-type="supplementary-material"}DD). In the inner nuclear layer (INL), GFP co-labeled with MGC marker anti-SOX9 ([Figures 6](#fig6){ref-type="fig"}G--6J); and in the ONL, GFP co-labeled with photoreceptor marker anti-recoverin ([Figures 6](#fig6){ref-type="fig"}K--6N). When analyzing donors 1--3 together, AAV5 showed the higher efficacy of transducing retinal cell types than AAV9 (14% ± 5% versus 3% ± 1%; [Figure 6](#fig6){ref-type="fig"}O), and AAV5 and ShH10Y445F showed higher potency in transduction of photoreceptors in the ONL than AAV9 (11% ± 3% and 5% ± 1% versus 3% ± 1%; [Figures 6](#fig6){ref-type="fig"}P and 6Q). Interestingly, we noticed that the photoreceptors of cadaveric human retinal explants were only efficiently infected by AAV9 ([Figures S7](#mmc1){ref-type="supplementary-material"}A and S7B), AAV5 ([Figure S7](#mmc1){ref-type="supplementary-material"}C), or ShH10Y445F ([Figure S7](#mmc1){ref-type="supplementary-material"}D) in the presence of intact photoreceptor segments ([Figures S7](#mmc1){ref-type="supplementary-material"}E--S7G). This suggests an important role for the segments in the photoreceptor uptake of AAV particles. In conclusion, transduction of AAV serotypes in human cadaveric retina was more successful at targeting both photoreceptors and MGCs than in hiPSC-derived retinal organoids. AAV5 at 3 × 10^10^ gc significantly outperformed AAV9 in the transduction of PRCs.

CRB2 Is Located in the Apical Membrane of iPSC-Derived and Retinal Pigment Epithelium {#sec2.7}
-------------------------------------------------------------------------------------

CRB2 but not CRB1 immunostaining was detected in first trimester human fetal retinal pigment epithelium (RPE) ([Figures S3](#mmc1){ref-type="supplementary-material"}D'--S3F′). This was confirmed by immuno-EM in first and second trimester human fetal RPE ([Figures 7](#fig7){ref-type="fig"}A and 7B). CRB2 labeling was located above the adherens junctions at and above the tight junctions in the apical membrane and microvilli of human fetal RPE. Spheroids of hiPSC-derived RPE are also generated during the differentiation method used ([@bib22], [@bib35], [@bib49]). These RPE spheroids initially attach to the periphery of the retinal organoids but can detach during culturing ([Figures 7](#fig7){ref-type="fig"}C, 7D, and 7D′). CRB1 could not be detected apically of β-catenin ([Figure 7](#fig7){ref-type="fig"}C) in hiPSC-derived RPE, but CRB2 was found apically of the adherens junction marker p120-catenin in DD160 hiPSC-derived RPE ([Figure 7](#fig7){ref-type="fig"}D). This pattern of localization was also found in hiPSC-derived RPE derived from hiPSC lines LUMC0080iCTRL12 ([Figures 7](#fig7){ref-type="fig"}E and [S7](#mmc1){ref-type="supplementary-material"}F) and LUMC0044iCTRL44 ([Figures 7](#fig7){ref-type="fig"}G and 7H). Immuno-EM of iPSC-derived RPE confirmed the apical staining for CRB2 above adherens junctions at and above the tight junctions in the apical membrane and microvilli. Aspecific staining was detected within melanin granules due to the presence of endogenous peroxidase in these structures ([Figures 7](#fig7){ref-type="fig"}I and 7I′). Electron microscopy of hiPSC-derived RPE also showed the presence of melanosomes with pigments, basally located mitochondria and basement membrane ([Figure 7](#fig7){ref-type="fig"}J, insert), and fibrous long-spacing collagen ([Figures 7](#fig7){ref-type="fig"}J and 7J′). RPE cells were also infected by AAV9, AAV5, and ShH10Y445F ([Figures S7](#mmc1){ref-type="supplementary-material"}H--S7K).Figure 7Human iPSC Retinal Pigment Epithelium Localize CRB2 at and above Tight Junctions in the Apical Membrane and MicrovilliImmuno-EM showed staining for CRB2 above adherens junctions at and above tight junctions in the apical membrane and in the microvilli in first (A) and second (B) trimester in human fetal RPE. Aspecific staining was detected within melanosomes (A and B) (asterisk). Immunohistochemistry did not detect CRB1 apically of β-catenin (C) in hiPSC RPE, but CRB2 was found apically of p120-catenin in LUMC0004iCTRL10 (D and D′), LUMC0080iCTRL12 (E and F), and LUMC0044iCTRL44 (G and H) human iPSC-derived RPE. RPE spheroids were found either attached to retinal organoids or became independent, detached spheroids (D′). Immuno-EM confirmed apical staining for CRB2 above adherens junctions at and above tight junctions in the apical membrane and in the microvilli (I and I′) (arrows). Aspecific staining was detected within pigmented melanosomes (I′) (asterisk). Electron microscopy of hiPSC-derived RPE also showed basally located mitochondria (J) (insert) and basement membrane (J) (insert arrowheads) and fibrous long-spacing collagen (J and J′). AJ, adherens junction; N, nuclei; μ, microvilli; TJ, tight junction; m, mitochondria. Scale bars (C, D, D′, E, F, G, H), 20 μm; (A, B, I, I′, J, J′, insert J), 1 μm.

Discussion {#sec3}
==========

In this study, we showed (1) that in human fetal retina during the first trimester of pregnancy CRB2 is the predominant CRB family member in radial glial progenitor cells; and that CRB1 onset of expression at the subapical region coincides with the maturation of the retina during the second trimester. (2) CRB2 but not CRB1 is expressed in the fetal RPE. (3) The onset of CRB protein expression in human fetal retina and RPE is recapitulated in hiPSC-derived retinal organoids and RPE. (4) *CRB1* RP patient retinal organoids develop disruptions at the OLM with misplaced photoreceptors. (5) AAV5 and ShH10Y445F serotypes are more potent than AAV9 serotype in infecting cultured retinal organoids. (6) AAV5-CMV-*GFP* is more efficient than AAV9-CMV-*GFP* to express GFP in PRCs in cultured human donor retinal explants. (7) Human PRCs are efficiently transduced only in the presence of photoreceptor segments.

In the human fetal retina, we found that CRB2 is the predominant CRB effector protein in the first trimester of pregnancy. *CRB2* is a gene expressed in several tissues, including the cerebral cortex ([@bib14]), with a crucial role during early development in both mice and humans. Mice lacking *Crb2* are embryonic lethal, with a critical role for the CRB2 protein during gastrulation in the epithelial-to-mesenchymal transition ([@bib39]). CRB2 protein variants in humans have been linked to a syndromic phenotype causing kidney and brain dysfunctions and lethality ([@bib15], [@bib42]) as well as to RP ([@bib12]). In the second trimester, CRB1 and CRB2 localized at the subapical region in apical villi of radial glial progenitor cells/MGCs and at the subapical region above the adherens junctions in the inner segments of PRCs. During the second trimester, the retina undergoes the birth of all adult cell types, and the retina is transitioning from a mitotic to post-mitotic state ([@bib20], [@bib34]). Retinal organoids go from an early highly cell-cycling state, in which Ki67 marks the entire NBL at DD28, toward a moderate cell-cycling state, in which Ki67 becoming restricted to the mid-NBL at DD120.

Interestingly, here we showed that the onset of CRB1 protein expression coincided with the maturation of the retinal organoids, and this finding is recapitulated in the human fetal retina. In early-stage retinal organoids, we found, as in the first trimester fetal retina, CRB2 but little CRB1 protein expression at the subapical region. In later-stage hiPSC-derived retinal organoids we found CRB2 and CRB1 protein expression at the subapical region as in second trimester fetal retina. We also found a recapitulation of CRB2 expression when comparing first trimester fetal RPE with hiPSC-derived RPE.

We present here the generation and characterization of *CRB1* patient-derived hiPSCs differentiated to retinal organoids. We demonstrate that patient retinal organoids give rise to a morphological significant phenotype even though variant CRB1 protein and its interaction partners (MUPP1, PALS1, and CRB2) are detected at the OLM. The data suggest disruptions at the OLM resulting in loss of adhesion between photoreceptors and MGCs. Decreased levels of CRB1 and CRB2 proteins at the OLM exacerbated retinal degeneration in mouse models ([@bib2], [@bib29], [@bib36]). Also, the volcanic-like cell protrusions and OLM disruptions in the patient retinal organoids show striking similarities to the morphological phenotype found in 3-month-old *Crb1*^*KO*^ and 8-month-old *Crb1*^*KO/C249W*^ RP mice ([@bib25], [@bib26], [@bib27]). Further studies are needed to elucidate the underlying effects of the variant CRB1 proteins on protein-protein interactions and downstream cell signaling pathways.

We hypothesize that retinal organoids could be a good model for evaluating transgene expression and biological activity due to their close mimicking of human fetal retinal development ([@bib35]). Our transduction studies on cadaveric human retinal explants showed a higher potency for AAV5 over AAV9 for transduction of photoreceptors. Also, the data suggest the higher efficacy of AAV5-CMV-*GFP* than AAV9-CMV-*GFP* or ShH10Y445F-CMV-*GFP* to express in PRCs and MGCs. In the absence of photoreceptor segments in the human retinal explants, AAV5-CMV-*GFP*, ShH10Y445F-CMV-*GFP*, and AAV9-CMV-*GFP* showed higher efficacy to express in MGCs than in PRCs. The latter tropism and expression potency data in cultured cadaveric human retinal explants are reproduced in retinal organoids that recapitalize second trimester fetal retina.

Previous subretinal injection studies in which AAV5 was administered in mice at postnatal day 0 (P0) or P30 have shown preferred transduction of P0 cone PRC and MGCs, but only of P30 rod and cone PRCs ([@bib44]). We hypothesize that this preference in transduction patterns of PRC and MGCs in immature versus mature retina is due to the presence or absence of matured photoreceptor segments. In mice, photoreceptor segments seem to be required for the efficient transduction of PRCs with AAV vectors ([@bib33]). A very interesting and clinically relevant finding is that photoreceptors in cultured cadaveric human retinal explants are only efficiently transduced when they have photoreceptor segments. Retinal organoids represent immature fetal retinas that contain PRCs but with yet very immature segments. We hypothesize that PRCs are transduced by AAV5, AAV9, and ShH10Y445F once the PRC segments are formed in sufficient number and size. In the absence of PRC segments, however, there is increased bioavailability of AAV vectors to target less-abundant/preferred receptors for AAV uptake, e.g., on MGCs. Interestingly, dependency on the presence of photoreceptor segments for photoreceptor transduction was observed for all three AAV serotypes (AAV5, AAV9, and ShH10Y445F), suggesting a putative common mechanism of active AAV uptake into photoreceptors. The inner segments are a putative site of receptor-dependent or -independent clathrin- and caveolae-mediated endocytosis ([@bib16]).

Our data suggest that for clinical gene therapy with AAV5, AAV9, or ShH10Y445F the target PRCs should have intact photoreceptors to become efficiently transduced. It also implies that the AAV vector particles should be able to reach the PRC segments during clinical surgical application. This condition of accessibility of PRC inner segments in human retina *in vivo* is met upon subretinal injection, as suggested by AAV5 or AAV9 infection of PRCs in non-human-primate retinas ([@bib7], [@bib46]). Our mice lacking CRB1, as well as the mice with reduced levels of CRB2, showed a compromised OLM. We further hypothesize from our previous studies in mice that the retinas of human patients with loss of CRB1, or expressing non-functional CRB1 variants, have a compromised OLM that allows increased passage of AAV viral particles across the adherence junctions to reach the AAV-receptor molecules on MGCs ([@bib28]).

Experimental Procedures {#sec4}
=======================

See further details in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Fetal Human Retinal Tissue {#sec4.1}
--------------------------

The use and collection of the material was approved by the Medical Ethics Committee of the Leiden University Medical Center (P08.087).

Adult Human Retinal Tissue {#sec4.2}
--------------------------

Tissue was collected in agreement with the guidelines of the ethics committee of the LUMC. Informed consent was obtained on the basis of the Declaration of Helsinki (World Medical Association).

Cell Culture and Retinal Organoid Differentiation {#sec4.3}
-------------------------------------------------

Human iPSCs (LUMC0004iCTRL10 \[[@bib13]\], LUMC0044iCTRL44 \[[@bib11]\], LUMC0080iCTRL12 \[[Figure S4](#mmc1){ref-type="supplementary-material"}A\], LUMC0116iCRB09, LUMC0117iCRB01, and LUMC0128iCRB01 \[[Figure S4](#mmc1){ref-type="supplementary-material"}B\]) were maintained on Matrigel (BD)-coated plates in mTeSR medium (STEMCELL Technologies) and passaged mechanically. Retinal organoid differentiation was carried out as previously reported ([@bib35], [@bib49]).

Electron Microscopy {#sec4.4}
-------------------

Immuno-EM was performed as described previously ([@bib19]). In brief, sections were incubated with antibody for 48 h, then incubated with appropriate secondary peroxidase anti-peroxidase for 2 h, then developed in a 2,2-diaminobenzidine solution for 4 min, and then the gold substitute silver peroxidase method applied.

Generation and Purification of the Viral Vectors {#sec4.5}
------------------------------------------------

The pAAV2-*eGFP* plasmids were generated previously and consist of the flanking inverted terminal repeats of AAV2, the full-length CMV promoter, or the human RLBP1 promoter, the *eGFP* cDNA, the Woodchuck posttranscriptional regulatory element, and the bovine growth hormone poly(A) ([@bib1], [@bib4], [@bib30]).

*In Vitro* Transduction of Human Donor Retina and Human Induced Pluripotent Stem Cell-Derived Retinal Organoids {#sec4.7}
---------------------------------------------------------------------------------------------------------------

*In vitro* transduction protocols for (1) human donor retina and (2) hiPSC-derived retinal organoids have been described previously ([@bib8], [@bib35]).

Statistical Method {#sec4.6}
------------------

All statistical analyses were performed using GraphPad Prism version 7 (GraphPad Software). All values are expressed as mean ± SEM. Multiple t tests were performed with the analyzed number of samples indicated in the figure legends. Immunohistochemistry was performed on iPSC-derived retinal organoids from three independent healthy and three independent *CRB1*-patient iPSC lines from two or more differentiations, with three to six sections examined per organoid. Immunohistochemistry was performed on at least two independent human fetal eyes per time point, with three to six sections examined per eye. Immuno-EM was performed on at least two independent human fetal eyes, iPSC-derived retinal organoids, and RPE for each time point. For AAV transduction studies, between three and six different sections from at least three different human donor retina or hiPSC-derived retinal organoids (one to two organoids from two independent differentiations analyzed) were used for quantification. Between three and five images per organoid and ten images per adult donor retina were analyzed.
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